Citigroup reiterated coverage on Vanda Pharmaceuticals with a new price target

2/11/21 12:14:48 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Citigroup reiterated coverage of Vanda Pharmaceuticals with a rating of and set a new price target of $18.00 from $14.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VNDA

Date	Price Target	Rating	Analyst
10/31/2024	$18.00	Buy	H.C. Wainwright
7/11/2024	$11.00	Overweight	Cantor Fitzgerald
2/25/2022	$24.00 → $12.00	Buy → Hold	Jefferies